PMID- 27445459
OWN - NLM
STAT- MEDLINE
DCOM- 20170403
LR  - 20181113
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 10
DP  - 2016
TI  - Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review 
      of clinical trials.
PG  - 2087-94
LID - 10.2147/DDDT.S107587 [doi]
AB  - Axial spondyloarthritis (Ax SpA) refers to chronic inflammatory rheumatic 
      diseases that mainly affect the axial skeleton, leading to erosions and new bone 
      formation in the sacroiliac joints and/or the spine. Ax SpA includes the 
      radiographic form of the disease, ie, ankylosing spondylitis (AS), and the 
      nonradiographic Ax SpA (non-Rx Ax SpA) forms. Anti-tumor necrosis factor alpha 
      (TNFalpha) agents are used in the treatment of Ax SpA in patients who do not respond 
      to or are intolerant to nonsteroidal anti-inflammatory drugs. In these patients, 
      anti-TNFalpha agents show promising results by targeting the inflammatory process and 
      providing symptomatic relief. Golimumab is a fully human anti-TNFalpha agent that is 
      currently approved for the treatment of both AS and non-Rx Ax SpA in Europe. This 
      review focuses on the results of clinical trials with golimumab for the treatment 
      of AS (GO-RAISE studies) and non-Rx Ax SpA (GO-AHEAD study) and on the effects of 
      this agent on imaging findings (radiographic progression, magnetic resonance 
      imaging inflammation) as well as on biological parameters. Overall, golimumab is 
      a valid therapeutic option in patients with AS and non-Rx Ax SpA in Europe.
FAU - Toussirot, Eric
AU  - Toussirot E
AD  - Clinical Investigation Center in Biotherapy, Intitut National de la Sante et de 
      la Recherche Medicale CIC-1431; Federation Hospitalo-Universitaire Integrated 
      Center for Research in inflammatory Diseases; Department of Rheumatology, 
      University Hospital of Besancon, Besancon, France; Department of Therapeutics; 
      Equipe d'accueil EA 4266: "Pathogenic Agents and Inflammation", University of 
      Franche-Comte
FAU - Vauchy, Charline
AU  - Vauchy C
AD  - Clinical Investigation Center in Biotherapy, Intitut National de la Sante et de 
      la Recherche Medicale CIC-1431.
FAU - Binda, Delphine
AU  - Binda D
AD  - Clinical Investigation Center in Biotherapy, Intitut National de la Sante et de 
      la Recherche Medicale CIC-1431.
FAU - Michel, Fabrice
AU  - Michel F
AD  - Department of Neuromuscular Examinations and Diseases, University Hospital of 
      Besancon, Besancon, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160701
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 91X1KLU43E (golimumab)
SB  - IM
EIN - Drug Des Devel Ther. 2017 Jan 11;11:175. PMID: 28138220
MH  - Anti-Inflammatory Agents, Non-Steroidal/pharmacology/*therapeutic use
MH  - Antibodies, Monoclonal/pharmacology/*therapeutic use
MH  - Antirheumatic Agents/pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Spondylitis, Ankylosing/*drug therapy
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
PMC - PMC4936813
OTO - NOTNLM
OT  - anti-TNFalpha
OT  - axial spondyloarthritis
OT  - golimumab
EDAT- 2016/07/23 06:00
MHDA- 2017/04/04 06:00
PMCR- 2016/07/01
CRDT- 2016/07/23 06:00
PHST- 2016/07/23 06:00 [entrez]
PHST- 2016/07/23 06:00 [pubmed]
PHST- 2017/04/04 06:00 [medline]
PHST- 2016/07/01 00:00 [pmc-release]
AID - dddt-10-2087 [pii]
AID - 10.2147/DDDT.S107587 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2016 Jul 1;10:2087-94. doi: 10.2147/DDDT.S107587. 
      eCollection 2016.